The global demand for high-quality antiretroviral (ARV) medicines continues to grow as countries strengthen HIV treatment programs. Anzavir R Tablets, containing Atazanavir 300mg and Ritonavir 100mg, are widely used as part of combination antiretroviral therapy (ART) for the treatment of HIV-1 infection.
Manufactured and exported by Cordium Pharmaceuticals Pvt. Ltd., Anzavir R Tablets are supplied to international pharmaceutical distributors, government procurement agencies, hospitals, NGOs, and healthcare organizations.
What is Anzavir R Tablet?
Anzavir R Tablet is a fixed-dose combination containing:
Atazanavir 300mg
Ritonavir 100mg
This combination belongs to the Protease Inhibitor (PI) class of antiretroviral medicines used for the management of HIV-1 infection in adults. Ritonavir acts primarily as a pharmacokinetic booster, increasing atazanavir blood levels by inhibiting its metabolism, thereby improving antiviral effectiveness.
Mechanism of Action of Anzavir R Tablets
Atazanavir
Atazanavir selectively inhibits the HIV-1 protease enzyme, preventing the cleavage of viral Gag and Gag-Pol polyproteins. Without this step, HIV produces immature, non-infectious viral particles that cannot establish productive infection.
Ritonavir
Ritonavir is administered at a low dose mainly as a CYP3A4 inhibitor. It slows the metabolism of atazanavir, increasing its plasma concentration and extending its duration of action, allowing more effective viral suppression.
Combined Effect
Together, Atazanavir and Ritonavir:
Reduce HIV viral replication.
Lower viral load.
Preserve immune function by supporting CD4 cell recovery.
Help delay progression to AIDS when used with other antiretroviral medicines.
Uses of Anzavir R Tablets
Anzavir R Tablets are indicated for:
Treatment of HIV-1 infection as part of combination antiretroviral therapy (ART).
Long-term viral suppression under physician supervision.
Management of HIV in treatment-naïve and selected treatment-experienced patients, according to applicable clinical guidelines and resistance patterns.
Important: Anzavir R Tablets are not a cure for HIV/AIDS and should always be used as prescribed by qualified healthcare professionals.
Advantages of Anzavir R Tablets
Once-daily dosing.
High antiviral efficacy in appropriate treatment regimens.
Ritonavir-boosted formulation enhances atazanavir exposure.
Trusted protease inhibitor-based therapy.
Manufactured under stringent quality standards.
Export Markets Served by Cordium Pharmaceuticals Pvt. Ltd.
Cordium Pharmaceuticals Pvt. Ltd. exports Anzavir R Tablets (Atazanavir 300mg/Ritonavir 100mg) to international markets, including:
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇵🇭 Philippines
🇻🇳 Vietnam
🇦🇪 UAE
🇸🇦 Saudi Arabia
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
🇺🇸 USA*
🇬🇧 UK*
🇿🇦 South Africa
*Subject to country-specific regulatory approvals and import requirements.
Why Choose Cordium Pharmaceuticals Pvt. Ltd.?
Cordium Pharmaceuticals Pvt. Ltd. is committed to delivering:
High-quality pharmaceutical formulations.
Reliable international export services.
Competitive pricing.
Timely global shipments.
Regulatory documentation support.
Partnership opportunities for distributors, importers, hospitals, NGOs, and government procurement agencies.
Frequently Asked Questions (FAQs)
Is Anzavir R Tablet used alone?
No. It is prescribed as part of a combination antiretroviral therapy (ART) regimen for HIV treatment.
What is the role of Ritonavir?
Ritonavir boosts the effectiveness of Atazanavir by slowing its metabolism and increasing drug exposure.
Who can import Anzavir R Tablets?
Licensed pharmaceutical distributors, hospitals, healthcare organizations, NGOs, and government procurement agencies, subject to local regulations.
Conclusion
Anzavir R Tablets (Atazanavir 300mg/Ritonavir 100mg) play an important role in modern HIV treatment by suppressing viral replication through protease inhibition while using ritonavir to enhance atazanavir exposure. Manufactured by Cordium Pharmaceuticals Pvt. Ltd., these tablets are available for export to multiple international markets, including Kenya, Nigeria, Ghana, Philippines, Vietnam, UAE, Saudi Arabia, Uzbekistan, Kazakhstan, USA, UK, and South Africa, supporting global access to quality antiretroviral medicines.
